Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell
Autors principals: Wec, Anna Z., Herbert, Andrew S., Murin, Charles D., Nyakatura, Elisabeth K., Abelson, Dafna M., Fels, J. Maximilian, He, Shihua, James, Rebekah M., de La Vega, Marc-Antoine, Zhu, Wenjun, Bakken, Russell R., Goodwin, Eileen, Turner, Hannah L., Jangra, Rohit K., Zeitlin, Larry, Qiu, Xiangguo, Lai, Jonathan R., Walker, Laura M., Ward, Andrew B., Dye, John M., Chandran, Kartik, Bornholdt, Zachary A.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808922/
https://ncbi.nlm.nih.gov/pubmed/28525755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2017.04.037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars